Nicolas Guilbaud

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.

Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.

Journal: Oncotarget

Published: November 19, 2019

eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.

eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer.

Journal: JCI insight

Published: April 29, 2018

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Journal: Investigational new drugs

Published: April 02, 2018

Actinic keratosis modelling in mice: A translational study.

Actinic keratosis modelling in mice: A translational study.

Journal: PloS one

Published: January 18, 2017

The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.

The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks.

Journal: Molecular cancer therapeutics

Published: November 11, 2016

Discovery bioanalysis and in vivo pharmacology as an integrated process: a case study in oncology drug discovery.

Discovery bioanalysis and in vivo pharmacology as an integrated process: a case study in oncology drug discovery.

Journal: Bioanalysis

Published: June 18, 2016

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

Journal: Cancer letters

Published: June 09, 2015

Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.

Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.

Journal: Bioorganic & medicinal chemistry letters

Published: March 12, 2015

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.

Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 08, 2014

Synthesis and biological evaluation of (-)-6-O-desmethylcryptopleurine and analogs.

Synthesis and biological evaluation of (-)-6-O-desmethylcryptopleurine and analogs.

Journal: Bioorganic & medicinal chemistry letters

Published: September 29, 2014

Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Journal: Investigational new drugs

Published: May 09, 2014

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.

Journal: Leukemia

Published: January 16, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026